FDA approves genetics-based cancer treatment that may be used in mesothelioma patients
A first-of-its-kind cancer drug has just been approved by the U.S. Food and Drug Administration for use in patients with many types of cancer, including malignant mesothelioma. The drug is manufactured by Bayer and is called larotrectinib, though it is sold under the brand name Vitrakvi. It is a genetics-based treatment that is provided based on the presence of a specific genetic biomarker in a patient’s cancer rather than on the type of cancer itself.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063